Fycompa

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
10-05-2023
Karakteristik produk Karakteristik produk (SPC)
10-05-2023

Bahan aktif:

perampanel

Tersedia dari:

Eisai GmbH

Kode ATC:

N03AX22

INN (Nama Internasional):

perampanel

Kelompok Terapi:

Antiepileptics, , Other antiepileptics

Area terapi:

Epilepsies, Partial

Indikasi Terapi:

Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

Ringkasan produk:

Revision: 32

Status otorisasi:

Authorised

Tanggal Otorisasi:

2012-07-23

Selebaran informasi

                                69
B. PACKAGE LEAFLET
70
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
FYCOMPA 2 MG, 4 MG, 6 MG, 8 MG, 10 MG, AND 12 MG FILM-COATED TABLETS
Perampanel
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Fycompa is and what it is used for
2.
What you need to know before you take Fycompa
3.
How to take Fycompa
4.
Possible side effects
5.
How to store Fycompa
6.
Contents of the pack and other information
1.
WHAT FYCOMPA IS AND WHAT IT IS USED FOR
Fycompa contains a medicine called perampanel. It belongs to a group
of medicines called
anti epileptics. These medicines are used to treat epilepsy - where
someone has repeated fits (seizures).
It has been given to you by your doctor to reduce the number of fits
that you have.
Fycompa is used in association with other antiepileptic drugs to treat
certain forms of epilepsy:
In adults, adolescents (aged 12 years and older), and children (from 4
to 11 years)
-
It is used to treat fits that affect one part of your brain (called a
“partial seizure”).
-
These partial seizures may or may not then be followed by a fit
affecting all of your brain
(called a “secondary generalisation”).
In adults and adolescents (aged 12 years and older), and children
(from 7 to 11 years)
-
It is also used to treat certain fits that affect all of your brain
from the start (called “generalised
seizures”) and cause convulsions or staring spells.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE FYCOMPA
DO NOT TAKE FYCOMPA:
-
If you have ever developed a severe skin rash or skin peeling
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Fycompa 2 mg film-coated tablets
Fycompa 4 mg film-coated tablets
Fycompa 6 mg film-coated tablets
Fycompa 8 mg film-coated tablets
Fycompa 10 mg film-coated tablets
Fycompa 12 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Fycompa 2 mg film-coated tablets
Each film-coated tablet contains 2 mg perampanel.
Excipient with known effect: Each 2 mg tablet contains 78.5 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 4 mg film-coated tablets
Each film-coated tablet contains 4 mg perampanel.
Excipient with known effect: Each 4 mg tablet contains 157.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 6 mg film-coated tablets
Each film-coated tablet contains 6 mg perampanel.
Excipient with known effect: Each 6 mg tablet contains 151.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 8 mg film-coated tablets
Each film-coated tablet contains 8 mg perampanel.
Excipient with known effect: Each 8 mg tablet contains 149.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 10 mg film-coated tablets
Each film-coated tablet contains 10 mg perampanel.
Excipient with known effect: Each 10 mg tablet contains 147.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
Fycompa 12 mg film-coated tablets
Each film-coated tablet contains 12 mg perampanel.
Excipient with known effect: Each 12 mg tablet contains 145.0 mg of
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Fycompa 2 mg film-coated tablets
Orange, round, biconvex tablet, engraved with E275 on one side and
‘2’ on other side
Fycompa 4 mg film-coated tablets
Red, round, biconvex tablet, engraved with E277 on one side and
‘4’ on other side
Fycompa 6 mg film-coated tablets
Pink, round, biconvex tablet, engrav
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 10-05-2023
Karakteristik produk Karakteristik produk Bulgar 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 13-01-2021
Selebaran informasi Selebaran informasi Spanyol 10-05-2023
Karakteristik produk Karakteristik produk Spanyol 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 13-01-2021
Selebaran informasi Selebaran informasi Cheska 10-05-2023
Karakteristik produk Karakteristik produk Cheska 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 13-01-2021
Selebaran informasi Selebaran informasi Dansk 10-05-2023
Karakteristik produk Karakteristik produk Dansk 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 13-01-2021
Selebaran informasi Selebaran informasi Jerman 10-05-2023
Karakteristik produk Karakteristik produk Jerman 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 13-01-2021
Selebaran informasi Selebaran informasi Esti 10-05-2023
Karakteristik produk Karakteristik produk Esti 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 13-01-2021
Selebaran informasi Selebaran informasi Yunani 10-05-2023
Karakteristik produk Karakteristik produk Yunani 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 13-01-2021
Selebaran informasi Selebaran informasi Prancis 10-05-2023
Karakteristik produk Karakteristik produk Prancis 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 13-01-2021
Selebaran informasi Selebaran informasi Italia 10-05-2023
Karakteristik produk Karakteristik produk Italia 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 13-01-2021
Selebaran informasi Selebaran informasi Latvi 10-05-2023
Karakteristik produk Karakteristik produk Latvi 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 13-01-2021
Selebaran informasi Selebaran informasi Lituavi 10-05-2023
Karakteristik produk Karakteristik produk Lituavi 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 13-01-2021
Selebaran informasi Selebaran informasi Hungaria 10-05-2023
Karakteristik produk Karakteristik produk Hungaria 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 13-01-2021
Selebaran informasi Selebaran informasi Malta 10-05-2023
Karakteristik produk Karakteristik produk Malta 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 13-01-2021
Selebaran informasi Selebaran informasi Belanda 10-05-2023
Karakteristik produk Karakteristik produk Belanda 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 13-01-2021
Selebaran informasi Selebaran informasi Polski 10-05-2023
Karakteristik produk Karakteristik produk Polski 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 13-01-2021
Selebaran informasi Selebaran informasi Portugis 10-05-2023
Karakteristik produk Karakteristik produk Portugis 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 13-01-2021
Selebaran informasi Selebaran informasi Rumania 10-05-2023
Karakteristik produk Karakteristik produk Rumania 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 13-01-2021
Selebaran informasi Selebaran informasi Slovak 10-05-2023
Karakteristik produk Karakteristik produk Slovak 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 13-01-2021
Selebaran informasi Selebaran informasi Sloven 10-05-2023
Karakteristik produk Karakteristik produk Sloven 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 13-01-2021
Selebaran informasi Selebaran informasi Suomi 10-05-2023
Karakteristik produk Karakteristik produk Suomi 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 13-01-2021
Selebaran informasi Selebaran informasi Swedia 10-05-2023
Karakteristik produk Karakteristik produk Swedia 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 13-01-2021
Selebaran informasi Selebaran informasi Norwegia 10-05-2023
Karakteristik produk Karakteristik produk Norwegia 10-05-2023
Selebaran informasi Selebaran informasi Islandia 10-05-2023
Karakteristik produk Karakteristik produk Islandia 10-05-2023
Selebaran informasi Selebaran informasi Kroasia 10-05-2023
Karakteristik produk Karakteristik produk Kroasia 10-05-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 13-01-2021

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen